Picture
SEARCH
What are you looking for?
Need help finding what you are looking for? Contact Us
Compare

PUBLISHER: Knowledge Sourcing Intelligence | PRODUCT CODE: 1917892

Cover Image

PUBLISHER: Knowledge Sourcing Intelligence | PRODUCT CODE: 1917892

Substance Abuse Treatment Market - Forecast from 2026 to 2031

PUBLISHED:
PAGES: 148 Pages
DELIVERY TIME: 1-2 business days
SELECT AN OPTION
PDF (Single User License)
USD 3950
PDF (Multiple User License)
USD 4550
PDF (Enterprise License)
USD 6950

Add to Cart

Substance Abuse Treatment Market is projected to expand at a 7.08% CAGR, attaining USD 25.455 billion in 2031 from USD 16.885 billion in 2025.

The substance abuse treatment market is a critical and expanding segment of the global healthcare system, dedicated to addressing the complex challenges of addiction through a continuum of medical, behavioral, and psychosocial interventions. This market encompasses a wide range of services, including detoxification, medication-assisted treatment (MAT), inpatient and outpatient rehabilitation, counseling, and long-term recovery support. Its growth is driven by the persistent and rising prevalence of substance use disorders (SUDs), the ongoing public health crisis of opioid addiction, evolving evidence-based treatment standards, and an increasing emphasis on holistic, patient-centered care models that address the multifaceted nature of addiction.

A fundamental and powerful driver of market expansion is the high and increasing global prevalence of substance use disorders. Addiction to opioids, alcohol, stimulants, and other substances represents a significant burden on public health, contributing to morbidity, mortality, and substantial socioeconomic costs. The sheer scale of affected individuals creates a sustained and growing demand for accessible, effective treatment services. This demand is further intensified by heightened public and governmental awareness of addiction as a chronic, treatable medical condition rather than a moral failing, which is reducing stigma and encouraging more individuals to seek help.

The ongoing opioid epidemic, particularly in North America, represents a specific and acute catalyst for market focus and innovation. The crisis has underscored the urgent need for effective treatment modalities and has driven significant policy changes, funding allocations, and clinical initiatives. This has led to a substantial expansion in the availability and utilization of medication-assisted treatment (MAT), which combines FDA-approved medications (such as buprenorphine, methadone, and naltrexone) with counseling and behavioral therapies. MAT is recognized as the gold standard for opioid use disorder, and its broader adoption is a major factor propelling the treatment market forward, improving retention in care and reducing the risk of fatal overdose.

Parallel to this, the market is being shaped by the widespread adoption and refinement of evidence-based treatment modalities. The field is moving beyond traditional, one-size-fits-all approaches toward interventions with demonstrated efficacy in clinical research. This includes specific behavioral therapies like cognitive-behavioral therapy (CBT), contingency management, and motivational interviewing, which are proven to reduce substance use and prevent relapse. The integration of these evidence-based practices into standard treatment protocols is improving patient outcomes, justifying reimbursement, and establishing higher standards of care across provider networks.

A significant trend is the shift toward holistic and individualized care models that recognize addiction as a biopsychosocial disorder. Effective treatment now routinely addresses co-occurring mental health conditions (dual diagnosis), underlying trauma, social determinants of health, and overall wellness. This comprehensive approach involves multidisciplinary teams of physicians, psychiatrists, therapists, and social workers creating personalized treatment plans. The focus on treating the whole person-not just the addiction-improves engagement, treatment retention, and long-term recovery success, making it a key differentiator for high-quality providers.

Geographically, North America maintains a dominant position in the market. This leadership is attributed to a high prevalence of SUDs, particularly opioid use disorder; a relatively well-developed treatment infrastructure; significant public and private funding for addiction services; and a regulatory environment that has progressively supported the expansion of treatment access, especially for MAT. The region's concentration of specialized treatment centers and ongoing policy initiatives to combat the addiction crisis further solidify its central role.

The service delivery model spans various levels of care to match patient acuity and need. This includes medically managed inpatient detoxification, residential rehabilitation for intensive therapy, partial hospitalization programs (PHP), intensive outpatient programs (IOP), and standard outpatient counseling. The trend is toward creating integrated care continua that allow patients to step up or down in intensity based on their progress, improving continuity of care and reducing gaps in service that can lead to relapse.

The competitive landscape includes large publicly traded healthcare providers specializing in behavioral health, national non-profit treatment organizations, and a vast number of local and regional clinics. Key competitive factors include clinical quality and outcomes, accreditation, the ability to provide integrated dual diagnosis care, payer network coverage, and the capacity to offer a full continuum of services. Strategic growth often involves mergers, acquisitions, and partnerships to expand geographic reach and service capabilities.

In conclusion, the substance abuse treatment market is evolving in response to a profound and persistent public health need. Its growth is fueled by the escalating prevalence of addiction, the specific urgency of the opioid crisis, and the maturation of more effective, compassionate, and comprehensive care models. Future market development will be shaped by efforts to further integrate addiction treatment into mainstream healthcare, address workforce shortages of qualified clinicians, overcome barriers to access in underserved areas, and secure sustainable reimbursement for evidence-based services. The market's trajectory reflects a critical societal effort to provide effective, dignified care for a chronic condition, with the goal of restoring health, function, and hope to individuals and communities.

Key Benefits of this Report:

  • Insightful Analysis: Gain detailed market insights covering major as well as emerging geographical regions, focusing on customer segments, government policies and socio-economic factors, consumer preferences, industry verticals, and other sub-segments.
  • Competitive Landscape: Understand the strategic maneuvers employed by key players globally to understand possible market penetration with the correct strategy.
  • Market Drivers & Future Trends: Explore the dynamic factors and pivotal market trends and how they will shape future market developments.
  • Actionable Recommendations: Utilize the insights to exercise strategic decisions to uncover new business streams and revenues in a dynamic environment.
  • Caters to a Wide Audience: Beneficial and cost-effective for startups, research institutions, consultants, SMEs, and large enterprises.

What do businesses use our reports for?

Industry and Market Insights, Opportunity Assessment, Product Demand Forecasting, Market Entry Strategy, Geographical Expansion, Capital Investment Decisions, Regulatory Framework & Implications, New Product Development, Competitive Intelligence

Report Coverage:

  • Historical data from 2021 to 2025 & forecast data from 2026 to 2031
  • Growth Opportunities, Challenges, Supply Chain Outlook, Regulatory Framework, and Trend Analysis
  • Competitive Positioning, Strategies, and Market Share Analysis
  • Revenue Growth and Forecast Assessment of segments and regions including countries
  • Company Profiling (Strategies, Products, Financial Information, and Key Developments among others.)

Substance Abuse Treatment Market Segmentation

  • By Substance
  • Alcohol
  • Opioids
  • Marijuana
  • Others
  • By Treatment Type
  • Behavioral Therapy
  • Medication-Assisted Treatment (MAT)
  • Detoxification
  • Others
  • By Application
  • In-Patient Facility
  • Outpatient Facility
  • By Geography
  • North America
  • USA
  • Canada
  • Mexico
  • South America
  • Brazil
  • Argentina
  • Others
  • Europe
  • Germany
  • France
  • United Kingdom
  • Spain
  • Italy
  • Others
  • Middle East and Africa
  • Saudi Arabia
  • UAE
  • Others
  • Asia Pacific
  • China
  • India
  • Japan
  • South Korea
  • Indonesia
  • Thailand
  • Taiwan
  • Others
Product Code: KSI061615957

TABLE OF CONTENTS

1. EXECUTIVE SUMMARY

2. MARKET SNAPSHOT

  • 2.1. Market Overview
  • 2.2. Market Definition
  • 2.3. Scope of the Study
  • 2.4. Market Segmentation

3. BUSINESS LANDSCAPE

  • 3.1. Market Drivers
  • 3.2. Market Restraints
  • 3.3. Market Opportunities
  • 3.4. Porter's Five Forces Analysis
  • 3.5. Industry Value Chain Analysis
  • 3.6. Policies and Regulations
  • 3.7. Strategic Recommendations

4. TECHNOLOGICAL OUTLOOK

5. SUBSTANCE ABUSE TREATMENT MARKET BY SUBSTANCE

  • 5.1. Introduction
  • 5.2. Alcohol
  • 5.3. Opioids
  • 5.4. Marijuana
  • 5.5. Others

6. SUBSTANCE ABUSE TREATMENT MARKET BY TREATMENT TYPE

  • 6.1. Introduction
  • 6.2. Behavioral Therapy
  • 6.3. Medication-Assisted Treatment (MAT)
  • 6.4. Detoxification
  • 6.5. Others

7. SUBSTANCE ABUSE TREATMENT MARKET BY APPLICATION

  • 7.1. Introduction
  • 7.2. In-Patient Facility
  • 7.3. Outpatient Facility

8. SUBSTANCE ABUSE TREATMENT MARKET BY GEOGRAPHY

  • 8.1. Introduction
  • 8.2. North America
    • 8.2.1. By Substance
    • 8.2.2. By Treatment Type
    • 8.2.3. By Application
    • 8.2.4. By Country
      • 8.2.4.1. USA
      • 8.2.4.2. Canada
      • 8.2.4.3. Mexico
  • 8.3. South America
    • 8.3.1. By Substance
    • 8.3.2. By Treatment Type
    • 8.3.3. By Application
    • 8.3.4. By Country
      • 8.3.4.1. Brazil
      • 8.3.4.2. Argentina
      • 8.3.4.3. Others
  • 8.4. Europe
    • 8.4.1. By Substance
    • 8.4.2. By Treatment Type
    • 8.4.3. By Application
    • 8.4.4. By Country
      • 8.4.4.1. Germany
      • 8.4.4.2. France
      • 8.4.4.3. United Kingdom
      • 8.4.4.4. Spain
      • 8.4.4.5. Italy
      • 8.4.4.6. Others
  • 8.5. Middle East and Africa
    • 8.5.1. By Substance
    • 8.5.2. By Treatment Type
    • 8.5.3. By Application
    • 8.5.4. By Country
      • 8.5.4.1. Saudi Arabia
      • 8.5.4.2. UAE
      • 8.5.4.3. Others
  • 8.6. Asia Pacific
    • 8.6.1. By Substance
    • 8.6.2. By Treatment Type
    • 8.6.3. By Application
    • 8.6.4. By Country
      • 8.6.4.1. China
      • 8.6.4.2. India
      • 8.6.4.3. Japan
      • 8.6.4.4. South Korea
      • 8.6.4.5. Indonesia
      • 8.6.4.6. Thailand
      • 8.6.4.7. Taiwan
      • 8.6.4.8. Others

9. COMPETITIVE ENVIRONMENT AND ANALYSIS

  • 9.1. Major Players and Strategy Analysis
  • 9.2. Market Share Analysis
  • 9.3. Mergers, Acquisitions, Agreements, and Collaborations
  • 9.4. Competitive Dashboard

10. COMPANY PROFILES

  • 10.1. Acadia Healthcare Company, Inc.
  • 10.2. Hazelden Betty Ford Foundation
  • 10.3. Promises Behavioral Health
  • 10.4. Caron Treatment Center
  • 10.5. Behavioral Health Group (Bhg)
  • 10.6. Crossroads Treatment Centers
  • 10.7. Sandstone Care
  • 10.8. American Addiction Centers, Inc.
  • 10.9. Mayo Clinic
  • 10.10. Pelago

11. APPENDIX

  • 11.1. Currency
  • 11.2. Assumptions
  • 11.3. Base and Forecast Years Timeline
  • 11.4. Key Benefits for the Stakeholders
  • 11.5. Research Methodology
  • 11.6. Abbreviations
Have a question?
Picture

Jeroen Van Heghe

Manager - EMEA

+32-2-535-7543

Picture

Christine Sirois

Manager - Americas

+1-860-674-8796

Questions? Please give us a call or visit the contact form.
Hi, how can we help?
Contact us!